Skip to main content
SpringerLink
Log in

Cardiovascular risk assessments in patients with cortisol-producing adenoma: impact of clinical features and genetic characteristics

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The causes of adrenal Cushing’s syndrome (CS) encompass a wide spectrum of adrenal cortisol proliferations that exhibit clinical and molecular heterogeneity. The aims of our study were to investigate whether clinical and molecular heterogeneity influences endothelial function and metabolic abnormalities in patients with cortisol-producing adenoma (CPA). We retrospectively enrolled 25 patients with CPA and 45 patients with essential hypertension (EH). All CPAs were studied by direct sequencing of PRKACA. Flow-mediated vasodilation (FMD), an index of vascular endothelial function, was significantly lower in CS and subclinical CS (SCS) groups than in the EH group. FMD impairment did not differ significantly between CS and SCS groups. No differences in FMD were seen between PRKACA mutant and wild-type groups. FMD correlated negatively with hemoglobin A1c (HbA1c) in both PRKACA mutant and wild-type groups, as well as in CS and SCS groups. After adrenalectomy, systolic blood pressure (SBP) and HbA1c decreased significantly from baseline in the CS group, and SBP and low-density lipoprotein cholesterol (LDL-C) decreased significantly from baseline in the SCS group. While SBP and LDL-C decreased significantly from baseline in patients with wild-type PRKACA, only HbA1c decreased from baseline in patients harboring PRKACA mutations. Our data showed that patients with CPA have impaired endothelial function compared with EH patients and suggest the need for strict monitoring of atherosclerosis, even in patients with SCS or without PRKACA mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig.1
Fig.2
Fig.3

Similar content being viewed by others

References

  1. Dekkers OM, Horváth-Puhó E, Jørgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM, Sørensen HT (2013) Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277–2284

    Article  PubMed  CAS  Google Scholar 

  2. Bancos I, Prete A (2021) Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab 106:3331–3353

    Article  PubMed  PubMed Central  Google Scholar 

  3. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533

    Article  PubMed  CAS  Google Scholar 

  4. Yanase T, Oki Y, Katabami T, Otsuki M, Kageyama K, Tanaka T, Kawate H, Tanabe M, Doi M, Akehi Y, Ichijo T (2018) New diagnostic criteria of adrenal subclinical Cushing’s syndrome: opinion from the Japan endocrine society. Endocr J 65(4):383–393

    Article  PubMed  CAS  Google Scholar 

  5. Di Dalmazi G, Pasquali R (2015) Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes. Curr Opin Endocrinol Diabetes Obes 22:163–168

    Article  PubMed  Google Scholar 

  6. Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T, Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Bertherat RM, J, Strom TM, Allolio B, (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 370:1019–1028

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Mete O, Duan K (2018) The many faces of primary aldosteronism and Cushing syndrome: a reflection of adrenocortical tumor heterogeneity. Front Med (Lausanne) 5:54

    Article  PubMed  Google Scholar 

  8. Kamilaris CDC, Hannah-Shmouni F, Stratakis CA (2020) Adrenocortical tumorigenesis: lessons from genetics. Best Pract Res Clin Endocrinol Metab 34:101428

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Rege J, Hoxie J, Liu CJ, Cash MN, Luther JM, Gellert L, Turcu AF, Else T, Giordano TJ, Udager AM, Rainey WE, Nanba K (2022) Targeted mutational analysis of cortisol-producing adenomas. J Clin Endocrinol Metab 107:e594–e603

    Article  PubMed  Google Scholar 

  10. Li X, Wang B, Tang L, Lang B, Zhang Y, Zhang F, Chen L, Ouyang J, Zhang X (2016) Clinical characteristics of PRKACA mutations in Chinese patients with adrenal lesions: a single-centre study. Clin Endocrinol (Oxf) 85:954–961

    Article  PubMed  CAS  Google Scholar 

  11. Baba R, Oki K, Gomez-Sanchez CE, Otagaki Y, Itcho K, Kobuke K, Kodama T, Nagano G, Ohno H, Yoneda M, Hattori N (2021) Genotype-specific cortisol production associated with Cushing’s syndrome adenoma with PRKACA mutations. Mol Cell Endocrinol 538:111456

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI (2015) PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol 172:677–685

    Article  PubMed  CAS  Google Scholar 

  13. Horikoshi T, Nakamura T, Yoshizaki T, Watanabe Y, Uematsu M, Kobayashi T, Nakamura K, Saito Y, Obata JE, Kugiyama K (2021) Impact of persistent endothelial dysfunction in an infarct-related coronary artery on future major adverse cardiovascular event occurrence in STEMI survivors. Heart Vessels 36:472–482

    Article  PubMed  Google Scholar 

  14. Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, Kario K, Sugiyama S, Munakata M, Ito H, Ueda S, Vlachopoulos C, Higashi Y, Inoue T, Node K (2018) Physiological diagnostic criteria for vascular failure. Hypertension 72:1060–1071

    Article  PubMed  CAS  Google Scholar 

  15. Xiao K, Liu M, Sun X, Zhang Y, Si J, Shi N, Sun L, Miao Z, Zhang H, Zhao T, Liu Z, Fan Z, Gao J, Li J (2023) Association of vascular endothelial function and quality of life in patients with ischemia and non-obstructive coronary artery disease. Heart Vessels 38:617–625

    Article  PubMed  Google Scholar 

  16. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Watanabe D, Morimoto S, Morishima N, Ichihara A (2021) Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism. Endocr Connect 10:578–587

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Yusoff FBM, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y (2017) Endothelial function is impaired in patients receiving antihypertensive drug treatment regardless of blood pressure level: FMD-J study (flow-mediated dilation Japan). Hypertension 70:790–797

    Article  PubMed  CAS  Google Scholar 

  19. Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Ishii S, Tomaru T, Horiguchi K, Okada S, Takata D, Rokutanda N, Horiguchi J, Tsushima Y, Oyama T, Takeyoshi I, Yamada M (2014) Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [rapid communication]. Endocr J 61:825–832

    Article  PubMed  CAS  Google Scholar 

  20. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Durmuş I, Korkmaz L, Celik S (2007) Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s syndrome. Endocrine 31:300–304

    Article  PubMed  CAS  Google Scholar 

  21. Akaza I, Yoshimoto T, Tsuchiya K, Hirata Y (2010) Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing’s syndrome. Endocr J 57:245–252

    Article  PubMed  Google Scholar 

  22. Tachibana H, Washida K, Kowa H, Kanda F, Toda T (2016) Vascular function in alzheimer’s disease and vascular dementia. Am J Alzheimers Dis Other Demen 31:437–442

    Article  PubMed  Google Scholar 

  23. Chandran DS, Jaryal AK, Jyotsna VP, Deepak KK (2011) Impaired endothelium mediated vascular reactivity in endogenous Cushing’s syndrome. Endocr J 58:789–799

    Article  PubMed  CAS  Google Scholar 

  24. Fallo F, Sonino N (2009) Should we evaluate for cardiovascular disease in patients with Cushing’s syndrome? Clin Endocrinol (Oxf) 71:768–771

    Article  PubMed  Google Scholar 

  25. Hatakeyama H, Inaba S, Takeda R, Miyamori I (2000) 11beta-hydroxysteroid dehydrogenase in human vascular cells. Kidney Int 57:1352–1357

    Article  PubMed  CAS  Google Scholar 

  26. Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M (2009) Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res 81:140–147

    Article  PubMed  CAS  Google Scholar 

  27. Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K (2008) Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr J 55:737–745

    Article  PubMed  CAS  Google Scholar 

  28. Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V (2012) Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012:525093

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 102:248–260

    Article  PubMed  CAS  Google Scholar 

  30. Nakanishi T, Ishigami Y, Otaki Y, Izumi M, Hiraoka K, Inoue T, Takamitsu Y (2002) Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure. Nephron 92:529–535

    Article  PubMed  CAS  Google Scholar 

  31. Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, Suzuki A, Sato M, Shimatsu A (2020) A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease. Endocr J 67:841–852

    Article  PubMed  CAS  Google Scholar 

  32. Matore BW, Banjare P, Singh J, Roy PP (2022) In silico selectivity modeling of pyridine and pyrimidine based CYP11B1 and CYP11B2 inhibitors: a case study. J Mol Graph Model 116:108238

    Article  PubMed  CAS  Google Scholar 

  33. Sakuma I, Suematsu S, Matsuzawa Y, Saito J, Omura M, Maekawa T, Nakamura Y, Sasano H, Nishikawa T (2013) Characterization of steroidogenic enzyme expression in aldosterone-producing adenoma: a comparison with various human adrenal tumors. Endocr J 60:329–336

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to the staff of the Department of Endocrinology and Hypertension at Tokyo Women’s Medical University for their assistance.

Funding

This work was funded by JSPS KAKENHI with Grant number 19K08497.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Daisuke Watanabe, Satoshi Morimoto, Noriko Morishima & Atsuhiro Ichihara

Authors
  1. Daisuke Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noriko Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsuhiro Ichihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Morimoto.

Ethics declarations

Conflict of interest

None of the authors have any potential conflicts of interest associated with this research.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, D., Morimoto, S., Morishima, N. et al. Cardiovascular risk assessments in patients with cortisol-producing adenoma: impact of clinical features and genetic characteristics. Heart Vessels 39, 65–74 (2024). https://doi.org/10.1007/s00380-023-02309-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-023-02309-x

Keywords

Search

Navigation